Possible severe piperacillin-tazobactam–associated drug-induced liver injury after re-exposure: a case report
- 1Department of Pharmacy, Affiliated Meishan Hospital of Chengdu University of Traditional Chinese Medicine/Traditional Chinese Medicine Hospital of Meishan, Meishan, China
Abstract
Background: Drug-induced liver injury (DILI) is an important cause of acute liver failure, and antimicrobial agents are among its most frequent causes. However, the association of clinically apparent liver injury with piperacillin-tazobactam is uncommon.
Case presentation: A 73-year-old man with normal liver biochemistry at admission received empirical piperacillin-tazobactam for suspected pulmonary and central nervous system infection. Liver biochemical abnormalities were first detected after 4 days of treatment. The patient’s aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels markedly decreased after the withdrawal of suspected hepatotoxic drugs and supportive treatment, whereas alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), and total bilirubin levels continued to increase over the same period. Piperacillin-tazobactam was subsequently restarted because of recurrent fever and concern about inadequately controlled bacterial infection. However, liver injury worsened sharply by then, with jaundice, elevations in marked aminotransferase and alkaline phosphatase levels, and an increase in international normalized ratio (INR). After evaluation of alternative causes, DILI was considered the most likely diagnosis. Piperacillin-tazobactam was discontinued again, and supportive treatment, including double plasma molecular adsorption system therapy, was provided; AST and ALT levels and INR improved substantially thereafter, whereas ALP, GGT, and total bilirubin levels remained abnormal, indicating that cholestasis had not yet resolved at discharge.
Conclusion: The temporal association, improvement after drug withdrawal, and pronounced deterioration after re-exposure support a diagnosis of possible piperacillin-tazobactam–associated DILI. Clear documentation and communication of suspected adverse drug reactions during transfers of care are essential to prevent inadvertent re-exposure.
Related
- Severe Thrombocytopenia Induced by Re‐Exposure to Piperacillin/Tazobactam: A Case Report in Critically Ill Patient With COVID‐19
- Protein Binding Determination of Cefepime, Flucloxacillin, Meropenem, Piperacillin and Tazobactam by Ultrafiltration in Critically Ill Patients: The Choice of Device Matters
- Prophylactic antibiotics for pancreaticoduodenectomy: study protocol for a multicenter randomized controlled trial comparing tazobactam/piperacillin versus ampicillin/sulbactam.
- Evaluation of Short Versus Long Course of Tobramycin Combined with Piperacillin/Tazobactam Against Antibiotic-Resistant Pseudomonas aeruginosa in a Hollow Fibre Infection Model
- Impact of inoculum effect on in vitro activity of intermittent and continuous piperacillin-tazobactam infusion against ESBL-producing Escherichia coli in a hollow-fiber infection model
BibTeX
@article{ren2026possible,
title = {{Possible severe piperacillin-tazobactam–associated drug-induced liver injury after re-exposure: a case report}},
author = {Jingwen Ren and Weifeng Yu and Yanli Dai},
journal = {Frontiers in Medicine},
year = {2026},
month = oct,
doi = {10.3389/fmed.2026.1977830},
url = {https://doi.org/10.3389/fmed.2026.1977830},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Possible severe piperacillin-tazobactam–associated drug-induced liver injury after re-exposure: a case report
AU - Jingwen Ren
AU - Weifeng Yu
AU - Yanli Dai
PY - 2026
DA - 2026/10/22
JO - Frontiers in Medicine
DO - 10.3389/fmed.2026.1977830
UR - https://doi.org/10.3389/fmed.2026.1977830
AB - Background: Drug-induced liver injury (DILI) is an important cause of acute liver failure, and antimicrobial agents are among its most frequent causes. However, the association of clinically apparent liver injury with piperacillin-tazobactam is uncommon. Case presentation: A 73-year-old man with normal liver biochemistry at admission received empirical piperacillin-tazobactam for suspected pulmonary and central nervous system infection. Liver biochemical abnormalities were first detected after 4 days of treatment. The patient’s aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels markedly decreased after the withdrawal of suspected hepatotoxic drugs and supportive treatment, whereas alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), and total bilirubin levels continued to increase over the same period. Piperacillin-tazobactam was subsequently restarted because of recurrent fever and concern about inadequately controlled bacterial infection. However, liver injury worsened sharply by then, with jaundice, elevations in marked aminotransferase and alkaline phosphatase levels, and an increase in international normalized ratio (INR). After evaluation of alternative causes, DILI was considered the most likely diagnosis. Piperacillin-tazobactam was discontinued again, and supportive treatment, including double plasma molecular adsorption system therapy, was provided; AST and ALT levels and INR improved substantially thereafter, whereas ALP, GGT, and total bilirubin levels remained abnormal, indicating that cholestasis had not yet resolved at discharge. Conclusion: The temporal association, improvement after drug withdrawal, and pronounced deterioration after re-exposure support a diagnosis of possible piperacillin-tazobactam–associated DILI. Clear documentation and communication of suspected adverse drug reactions during transfers of care are essential to prevent inadvertent re-exposure.
SN - 2296-858X
ER -